A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT04072952. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Open Label, Dose Escalation, and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer, Who Have Received Prior Hormonal Therapy and Chemotherapy in the Locally Advanced/Metastatic Setting
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was a Phase 1/2 dose escalation and cohort expansion study and assessed the safety, tolerability and anti-tumor activity of ARV-471 alone and in combination with palbociclib (IBRANCE®) in participants with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) locally advanced or mBC, who had received prior hormonal therapy and chemotherapy in the locally advanced/metastatic setting.
Study identification
- NCT ID
- NCT04072952
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 219 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 22, 2019 (Actual)
- Primary completion
- Sep 13, 2024 (Actual)
- Completion
- Mar 5, 2026 (Actual)
- Last update posted
- Sep 29, 2026
2019 – 2026
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Trial Site | Palo Alto | California | 94304 | — |
| Clinical Trial Site | San Francisco | California | 94158 | — |
| Clinical Trial Site | Santa Monica | California | 90404 | — |
| Clinical Trial Site | Norwalk | Connecticut | 06856 | — |
| Clinical Trial Site | Fort Myers | Florida | 33901 | — |
| Clinical Trial Site | Tampa | Florida | 33612 | — |
| Clinical Trial Site | Chicago | Illinois | 60637 | — |
| Clinical Trial Site | Boston | Massachusetts | 02114 | — |
| Clinical Trial Site | Boston | Massachusetts | 02215 | — |
| Clinical Trial Site | Ann Arbor | Michigan | 48109 | — |
| Clinical Trial Site | St Louis | Missouri | 63110 | — |
| Clinical Trial Site | East Brunswick | New Jersey | 08816 | — |
| Clinical Trial Site | The Bronx | New York | 10461 | — |
| Clinical Trial Site | Charlotte | North Carolina | 28204 | — |
| Clinical Trial Site | Nashville | Tennessee | 37203 | — |
| Clinical Trial Site | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04072952, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 29, 2026 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04072952 live on ClinicalTrials.gov.